novo nordisk weight loss drugs - Search News

Ozempic Among Next Drugs Up for Medicare Price Negotiations

Hosted on MSN · 1d

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,

The New York Times · 1d

Medicare to Negotiate Lower Prices for Weight-Loss Drugs

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Ars Technica · 1d

Wegovy and Ozempic top list of 15 drugs up for next price negotiations

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year, with resulting bargained prices going into effect in 2027.

Novo Nordisk stock prices drop

The Motley Fool on MSN · 1d

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the company said semaglutide 7.2 milligram (mg) injections over a 72-week period resulted in an average weight loss of 20.7%, better than the 17.5% weight loss achieved in a prior trial of semaglutide 2.4 mg injections.

YAHOO!Finance · 7h

Is Novo Nordisk Stock a Buy?

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Over the last five years,

Washington Examiner · 1d

Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.

22hon MSN

E-sellers of compounded weight-loss drugs fail to reveal risks, research shows

By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo ...

Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results